IMRX
Immuneering Corporation
$5.22
+0.00%
2026-05-08
About Immuneering Corporation
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
Forward P/E
-3.84
EPS (TTM)
$-1.27
ROE
-43.1%
Profit Margin
0.0%
Debt/Equity
1.75
Price/Book
1.54
Beta
0.36
Market Cap
$336.4M
Avg Volume (10D)
772K
Recent Breakout Signals
No recent breakout signals detected for IMRX.
Recent Price Range (60 Days)
60D High
$6.22
60D Low
$4.67
Avg Volume
847K
Latest Close
$5.22
Get breakout alerts for IMRX
Sign up for Breakout Scanner to receive daily notifications when IMRX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Immuneering Corporation (IMRX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IMRX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IMRX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.